Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

A new study looked at the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. At the end of the 72 ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

A popular weight-loss jab has been approved to treat a common sleep disorder in Australia, after a new ruling by the medicine ...

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

No drug is without potential side effects, and there are five major ones that people taking Ozempic, Wegovy or Mounjaro are ...